Journal
CURRENT PHARMACEUTICAL DESIGN
Volume 21, Issue 14, Pages 1899-1907Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1381612821666150302120047
Keywords
Albumin; fusion protein; intracellular targeting; fatty acid-modified drugs; co-delivery
Categories
Ask authors/readers for more resources
Fusion proteins have been well-studied and widely applied in biopharmaceutics. Albumin fusion proteins are simple to construct, easy to purify, and stable to formulate. One main application of fusion protein is to extend the plasma half-life of therapeutic proteins and peptides. Albiglutide for diabetes treatment is the first albumin fusion protein drug approved by FDA. Balugrastim and other albumin fusion proteins have been evaluated in clinical trials. Taking advantage of the physiological functions of albumin, albumin fusion proteins can also been applied to act on an essential intracellular target and carry fatty acid-modified drugs. This novel approach makes it possible to co-deliver two different types of drug to one tumor cell for synergistic cytotoxicity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available